Quantitative phase analyses through the rietveld method with X-ray powder diffraction data of heat-treated carbamazepine form III

Journal of Pharmaceutical Sciences

Volumn 100, Issue 7, 2011, Pages 2658-2664

  Antonio, Selma Gutierrez ^a   Benini, Fernanda Ribeiro ^a   Ferreira, Fabio Furlan ^b   Rosa, Paulo César Pires ^c   De Oliveira Paiva santos, Carlos ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b UNIVERSIDADE FEDERAL DO ABC   (Brazil)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Carbamazepine; Crystal structure; Crystallography; Polymorphism; Quantitative phase analysis; Rietveld method; Solid state stability; Synchrotron; X ray powder diffractometry

Indexed keywords

CARBAMAZEPINE;

ARTICLE; HEAT TREATMENT; QUANTITATIVE ANALYSIS; SYNCHROTRON RADIATION; X RAY POWDER DIFFRACTION;

EID: 79955609635     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22482     Document Type: Article

References (29)

1. Treiman DM. 2010. Management of refractory complex partial seizures: Current state of the art. Neuropsychiatr Dis Treat 6: 297-308.
2. Teruo O, Kishimoto A. 1998. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psych Clin Neurosci 52: 3-12.
3. Weisler RH. 2006. Carbamazepine extended-release capsules in bipolar disorder. Neuropsychiatr Dis Treat 2(1): 3-11.
4. Grzesiak AL, Lang M, Kim K, Matzger AJ. 2003. Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. J Pharm Sci 92(11): 2260-2271.
5. Krahn FU, Mielck JB. 1987. Relations between several polymorphic forms and the dihydrate of carbamazepine. Pharm Acta Helv 62: 247-254.
6. McMahon LE, Timmins P, Williams AC, York P. 1996. Characterization of dihydrates prepared from carbamazepine polymorphs. J Pharm Sci 85(10): 1064-1069.
7. Fleischman SG, Kuduva SS, McMahon JA, Moulton B, Walsh RDB, Rodríguez-Hornedo N, Zaworotko MJ. 2003. Crystal engineering of the composition of pharmaceutical phases: Multiple-component crystalline solids involving carbamazepine. Cryst Growth Des 3(6): 909-919.
8. Reboul JP, Cristau B, Soyfer JC, Astier JP. 1981. 5H-Dibenz[b, f]azepinecarboxamide-5 (carbamazepine). Acta Crystallograph B 37(10): 1844-1848.
9. Himes VL, Mighell AD, De Camp WH. 1981. Structure of carbamazepine: 5H-dibenz[b, f]azepine-5-carboxamide. Acta Crystallograph B 37(12): 2242-2245.
10. Lang M, Kampf JW, Matzger AJ. 2002. Form IV of carbamazepine. J Pharm Sci 91: 1186-1190.
11. Food and Drug Administration. 2007. Guidance for industry: ANDAs: Pharmaceutical solid polymorphism-chemistry, manufacturing, and controls information. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER).
12. Ferreira FF, Antonio SG, Rosa PCP, Paiva-Santos CO. 2010. Crystal structure determination of mebendazole form A using high-resolution synchrotron X-ray powder diffraction data. J Pharm Sci 99(4): 1734-1744.
13. Rietveld HM. 1969. A profile refinement method for nuclear and magnetic structures. J Appl Crystallogr 2: 65-71.
14. Young RA. 1993. (Reprinted 1996). The Rietveld method. 2nd ed. New York: Oxford University Press.
15. 6 double perovskite. J Synchrot Radiat 13: 46-53.
16. Coelho AA. 2007. Topas academic. 4.1 Brisbane, Australia: Coelho Software, Topas Academic.
17. Coelho AA. 2003. Indexing of powder diffraction patterns by iterative use of singular value decomposition. J Appl Crystallogr 36(1): 86-95.
18. 3. J Appl Crystallogr 20: 79-83.
19. Young RA, Desai P. 1989. Archiwun Nauki o Materialach; pp 71-90.
20. Cheary RW, Coelho AA. 1998. Axial divergence in a conventional X-ray powder diffractometer. I. Theoretical foundations. J Appl Crystallogr 31(6): 851-861.
21. Cheary RW, Coelho AA. 1998. Axial divergence in a conventional X-ray powder diffractometer. II. Realization and evaluation in a fundamental-parameter profile fitting procedure. J Appl Crystallogr 31(6): 862-868.
22. Cheary RW, Coelho A. 1992. A fundamental parameters approach to X-ray line-profile fitting. J Appl Crystallogr 25(2): 109-121.
23. Toby BH 2006. R factors in Rietveld analysis: How good is good enough? Powder Diffr 21: 67-70.
24. Ghita OR, Beard MA, McCabe J, Bottom R, Richmond J, Evans KE. 2008. A study into first and second order thermal transitions of materials using spectral-DSC. J Mat Sci 43(14): 4988-4995.
25. Behme RJ, Brooke D. 1991. Heat of fusion measurement of a low melting polymorph of carbamazepine that undergoes multiple-phase changes during differential scanning calorimetry analysis. J Pharm Sci 80: 986-990.
26. Urakami K, Shono Y, Higashi A, Umemoto K, Godo M. 2002. A novel method for estimation of transition temperature for polymorphic pairs in pharmaceuticals using heat of solution and solubility data. Chem Pharm Bull 50: 263-267.
27. Getsoian A, Lodaya RM, Blackburn AC. 2008. One-solvent polymorph screen of carbamazepine. Int J Pharm 348: 3-9.
28. McGregor C, Saunders MH, Buckton G, Saklatvala RD. 2004. The use of high-speed differential scanning calorimetry (Hyper-DSC(TM)) to study the thermal properties of carbamazepine polymorphs. Thermochim Acta 417(2): 231-237.
29. Kobayashi Y, Ito S, Itai S, Yamamoto K. 2000. Physicochemical properties and bioavailability of carbamazepine polymorphs and dihydrate. Int J Pharm 193(2): 137-146.